BUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance

Reuters

Feb 20

BUZZ-Australia's <a href="https://laohu8.com/S/TLX.AU">Telix Pharmaceuticals</a> soars on upbeat FY26 revenue guidance

** Shares of Telix Pharmaceuticals TLX.AX rise as much as 9.5% to A$10, on track for best session since mid-October, 2025

** Stock at highest level since February 11; best performer on S&P/ASX 200 index

** Co announces revenue guidance of $950 million to $970 million for FY26, higher than $803.8 million in FY25

** This is despite co posting a non-material loss before tax of $5.3 million for 2025, compared to a profit of $38 million a year earlier

** Stock down 12% YTD

(Reporting by Anjali Singh in Bengaluru)

((anjali.singh2@thomsonreuters.com; ))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612234854"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612234854\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612234854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 07:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612234854","market":"nz","top_or_hot":-1,"title":"BUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> soars on upbeat FY26 revenue guidance</title></head><body><p>** Shares of Telix Pharmaceuticals <span>TLX.AX</span> rise as much as 9.5% to A$10, on track for best session since mid-October, 2025</p><p>** Stock at highest level since February 11; best performer on S&amp;P/ASX 200 index</p><p>** Co <span>announces</span> revenue guidance of $950 million to $970 million for FY26, higher than $803.8 million in FY25</p><p>** This is despite co posting a non-material loss before tax of $5.3 million for 2025, compared to a profit of $38 million a year earlier</p><p>** Stock down 12% YTD</p><p>(Reporting by Anjali Singh in Bengaluru)</p><p>((anjali.singh2@thomsonreuters.com; ))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 07:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> soars on upbeat FY26 revenue guidance</title></head><body><p>** Shares of Telix Pharmaceuticals <span>TLX.AX</span> rise as much as 9.5% to A$10, on track for best session since mid-October, 2025</p><p>** Stock at highest level since February 11; best performer on S&amp;P/ASX 200 index</p><p>** Co <span>announces</span> revenue guidance of $950 million to $970 million for FY26, higher than $803.8 million in FY25</p><p>** This is despite co posting a non-material loss before tax of $5.3 million for 2025, compared to a profit of $38 million a year earlier</p><p>** Stock down 12% YTD</p><p>(Reporting by Anjali Singh in Bengaluru)</p><p>((anjali.singh2@thomsonreuters.com; ))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL6N3ZF191:1","article_id":"2612234854","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612234854","pubTimestamp":1771544263,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance** Shares of Telix Pharmaceuticals TLX.AX rise as much as 9.5% to A$10, on track for best session since mid-October, 2025** Stock at highest level since February 11; best performer on S&P/ASX 200 index** Co announces revenue guidance of $950 million to $970 million for FY26, higher than $803.8 million in FY25** This is despite co posting a non-material loss before tax of $5.3 million for 2025, compared to a profit of $38 million a year earlier** Stock down 12% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"BUZZ-澳大利亚Telix Pharmaceuticals因乐观的26财年收入指引而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9},"content_text":"BUZZ-Australia's Telix Pharmaceuticals soars on upbeat FY26 revenue guidance** Shares of Telix Pharmaceuticals TLX.AX rise as much as 9.5% to A$10, on track for best session since mid-October, 2025** Stock at highest level since February 11; best performer on S&P/ASX 200 index** Co announces revenue guidance of $950 million to $970 million for FY26, higher than $803.8 million in FY25** This is despite co posting a non-material loss before tax of $5.3 million for 2025, compared to a profit of $38 million a year earlier** Stock down 12% YTD(Reporting by Anjali Singh in Bengaluru)((anjali.singh2@thomsonreuters.com; ))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}